“My goals,” he explains, “are to bring regenerative cannabis to the market, to bring true medicine to the people where organic is organic. Where our fertilizers and our feeds are sourced within 250 miles from the farm, and to make our brand known as a truly holistic company.”
From a branding and marketing standpoint, I’m convinced that until we bridge the science of the medical market with the consumer’s experience in the recreational market, ignorance will linger and the market will plateau with over-saturated brands and buzzwords that deflate the meaning of efficacy. As an example, look at the bubble of CBD in the last year to see consumers swooning over science that is yet to be regulated and false or misleading packaging that profligates on shelves across the US.
13 Seeds generated $230,000 revenue in the 2019 financial year through sales of its 15 food products and 10 skin care products.
Situated at La Trobe University, the facility seeks to optimise production of active components in medicinal plants and identify their potential mode of action in various diseases.
The current dissatisfaction rate with the delivery system of medical cannabis in Australia according to the MCUA survey is a whopping 86%. Also, it’s not unusual for appointments to cost patients anything between $100 & $1000 just to discuss the possibility of getting a prescription from a medical professional who is likely as not to be trained properly to make an informed decision anyway.
Medicinal cannabis products are just a legalisation away since New Zealand company, Medical Kiwi has partnered with two overseas companies.
It’s as about as clear as can be. Will the incumbent Federal Govt pay attention or just keep the blinkers on? A special Roy Morgan online survey shows more than three-fifths of Australians (62%) don’t want the Federal Government to overturn the new ACT law decriminalising cannabis for personal use, which is set to come into effect in 2020. This is well over double the percentage who says they do want the Federal Government to step in (27%), while 11% can’t say either way.
As always it depends who you speak to.
The industry-led study is a collaboration between the NSW and Australian Governments, medicinal cannabis research company Cann Group Ltd, agriculture technology company Aglive, Southern Cross University and the University of Newcastle.
Clinical studies are about to get underway at an Australian university, to track changes in actual dementia patients to see if cannabis can help with dementia and related issues.